嵌合抗原受體 (CAR) T細胞免疫療法:競爭情形，技術，開發平台分析

本報告提供嵌合抗原受體 (CAR) T細胞免疫療法調查分析，以上市、開發平台藥物為焦點，提供開發平台的競爭情形，上市藥的資訊，現在、未來市場，開發中產品，主要企業等系統性資訊。

目錄

• 報告的介紹
• 摘要整理概述
• 摘要整理
• 簡介
• 嵌合抗原受體 (CAR) T細胞
• 過程
• CAR、世代
• CAR-T細胞的優點
• CAR-T細胞療法的不利事件
• CAR-T細胞的現有技術的限制
• CAR-T細胞療法:分析
• CAR-T共同研究交易
• CAR-T細胞療法的共同研究、交易年
• 共同研究、交易額趨勢
• 未來開發的合作企業
• CAR-T收購交易
• CAR-T細胞療法的收購趨勢
• CAR-T細胞療法的收購產品:各大企業
• CAR-T細胞開發的新設施
• JCAR015
• CAR-T許可證的機會
• 開發平台方案
• 開發中的開發中產品:概要
• 開發中的開發中產品:各企業
• CAR-T細胞治療領域、企業
• CAR-T細胞的標的抗原
• CAR-T療法:臨床實驗、完成年
• CAR-T細胞技術、參與企業
• CAR-T安全開關、參與企業
• 未來的CAR-T治療的企業
• 開發平台簡介
• 其他的活躍企業
• Miltenyi Biotec
• ZMKS International Cancer Therapies Biotechnologies Co. Ltd.
• 比CAR更好的未來技術
• 市場的推動要素
• 市場障礙
• SWOT分析
• 調查手法
• 諮詢服務

"Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Pipeline and Market Analysis, 2018", report provides comprehensive Insight about marketed and pipeline drugs across this Immunotherapy. The report provides the detailed analysis of 190+ products along with 60+ companies involved. Celgene Corporation and bluebird bio has been granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for bb2121 Anti-BCMA CAR-T Cell Therapy for Relapsed and Refractory Multiple Myeloma.

Products covered by Phase

• Phase II, Phase I and IND
• Pre-clinical and Discovery

Overview of pipeline development activities for Chimeric Antigen Receptor (CAR) T cell Immunotherapy

Pipeline analysis of 190+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Report contains the development and sale activities for marketed drugs.

Therapeutic segmentation of products for Chimeric Antigen Receptor (CAR) T cell Immunotherapy

The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this Immunotherapy.

Methodology

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts.

Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope

• The report provides competitive pipeline landscape of Chimeric Antigen Receptor (CAR) T cell Immunotherapy
• The report provides the marketed drugs information including its sales, development activities and details of patent expiry
• The report provides the insight of current and future market for Chimeric Antigen Receptor (CAR) T cell Immunotherapy
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the Chimeric Antigen Receptor (CAR) T cell Immunotherapy pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Chimeric Antigen Receptor (CAR) T cell Immunotherapy and also provide company profiling
• Pipeline products coverage based on various stages of development ranging from mid stage till discovery stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to Buy

• Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
• Establish a comprehensive understanding of the current pipeline scenario across Chimeric Antigen Receptor (CAR) T cell Immunotherapy to formulate effective R&D strategies
• Assess challenges and opportunities that influence Chimeric Antigen Receptor (CAR) T cell Immunotherapy R&D
• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Devise corrective measures for pipeline projects by understanding Chimeric Antigen Receptor (CAR) T cell Immunotherapy pipeline depth and focus of Indication therapeutics
• Developing strategic initiatives to support your drug development activities
• Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Chimeric Antigen Receptor (CAR) T cell Immunotherapy to enhance and expand business potential and scope
• Provides strategically significant competitor information, analysis, and Insight to formulate effective R&D development strategies
• Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive drugs
• Gaining a full picture of the Competitive Landscape for Evidence based Decisions

Table of Contents

Overview

Chimeric antigen receptor (CAR) T-cells

History

CARs and Generations

Advantages of CAR-T cells

Adverse Events with CAR T-cell Therapy

Limitations of Existing Technologies for CAR T-Cells

Marketed Products

Kymriah: Novartis

Product Description

Regulatory Milestones

Research and Development

Other Clinical Activities

Product Development Activities

Pipeline Therapeutics

Clinical Phase Products

Non-Clinical Phase Products

Competitive Landscape

Comparative Analysis

Mid Stage Products (Phase II)

Comparative Analysis

AU105: Aurora BioPharma

Product Description

Research and Development

Product Development Activities

(The list continues)

Early Stage Products (Phase I)

Comparative Analysis

IND Stage Products

Comparative Analysis

Unknown Stage Products

Comparative Analysis

Pre-clinical and Discovery Products

Comparative Analysis

Therapeutic Assessment : Clinical Phase Products

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Appendix

List of Tables

• Table 1: CARs Generations
• Table 2: CARs Generations-Associated Target Antigens and Indications
• Table 3: Total Products for CART Cell therapy
• Table 4: Mid Stage Products (Phase II)
• Table 5: Early Stage Products (Phase I)
• Table 6: IND Stage Products
• Table 7: Unknown Stage Products
• Table 8: Pre-clinical Stage Products
• Table 9: Discovery Stage Products
• Table 10: Assessment by Route of Administration
• Table 11:: Assessment by Stage and Route of Administration

List of Figures

• Figure 1: Total Products for CART Cell therapy
• Figure 2: Mid Stage Products (Phase II)
• Figure 3: Early Stage Products (Phase I)
• Figure 4: IND Stage Products
• Figure 5: Unknown Stage Products
• Figure 6: Pre-clinical and Discovery Stage Products
• Figure 7: Assessment by Route of Administration
• Figure 8: Assessment by Stage and Route of Administration